Guselkumab in the treatment of inflammatory bowel diseases

Czech version

Authors: M. Lukáš
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in: Gastroent Hepatol 2025; 79(5): 384-389
Category: Review Article
doi: https://doi.org/10.48095/ccgh2025384

Overview

Guselkumab is a human monoclonal antibody IgG1 targeted to the IL-23p19 subunit engaging receptor CD64, inducing neutralization of IL-23, and capturing of IL-23 in the myeloid cells. Positive results from registration studies QUASAR and GALAXI allowed an approval of guselkumab for clinical practice in patients with moderately to severely active ulcerative colitis and Crohn’s disease. In these studies, a high safety drug profile was also confirmed. The same dosage for both diseases and subcutaneous induction significantly differentiate guselkumab from other anti-IL-23p19 inhibitors.

Keywords:

guselkumab – anti-IL-23 therapy – inflammatory bowel disease – ulcerative colitis – Crohn’s disease

Sources

1. Sachen KL, Hammaker D, Sarabia I et al. Guselkumab binding to CD64 IL-23-producing myleoid cells enhances potency for neutralizing IL-23 signaling. Front Immunol 2025; 16 : 1532852. doi: 10.3389/fimmu.2025.1532852.

2. Panaccione R, Feagan BG, Afzali A et al. Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn‘s disease (GALAXI-2 and GALAXI-3): 48 week results from two phase 3, randomized, placebo and active comparator-controlled, double blind, triple dummy trial. Lancet 2025; 406 (10501): 358–375. doi: 10.1016/S0140-6736 (25) 00681-6.

3. Pugliano CL, Fueng-Hin Liang R, Ruffa A et al. Practical considerations for the use of IL-23p19 inhibitors in inflammatory bowel disease: how to choose between them and why is matters? J Crohns Colitis 2025; jjaf144. doi: 10.1093/ecco-jcc/jjaf144.

4. SmPC Tremfya, datum revize textu 24. 7. 2025.

5. Hart A, Panaccione R, Steinwurz F et al. Efficacy and safety of guselkumab subcutaneous induction and maintenance in participants with moderately to severely active Crohn‘s disease: results from the phase 3 GRAVITI study. Gastroenterology 2025; 169 (2): 308–325. doi: 10.1053/j.gastro.2025.02.033.

6. Rubin DT, Allegretti JR, Panés J et al. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenace studies. Lancet 2025; 405 (10472): 33–49. doi: 10.1016/S0140-67 36 (24) 01927-5.

7. Lichtenstein GR, Allegrettl JR, Rubin DT et al. Efficacy and safety of guselkumab for ulcerative colitis through week 92 during the QUASAR long-term extension study. 2025 [online]. Dostupné z: https: //www.jnjmedicalcloud.ch/assets/blt34dccb4f0c7ab035/blt54557d603c3a767d/68400744868ed3634939c63b/ DDW_2025_Reflow_JnJ_Data_Deck.pdf.

8. Schmitt H, Billmeier U, Dieterich W et al. Expansion of IL-23 receptor bearing TNFR2+ T cells is asscociated with molecular resistence to anti-TNF therapy in Crohn‘s disease. Gut 2019; 68 (5): 814–828. doi: 10.1136/gutjnl-2017 -⁠ 315671.

ORCID autora

M. Lukáš 0000-0002-1463-3840.

Korespondenční autor

prof. MUDr. Milan Lukáš, CSc., AGAF

Klinické a výzkumné centrum pro střevní záněty

Klinické centrum ISCARE a. s. a 1. LF UK Praha

Českomoravská 19

190 00 Praha 9

milan.lukas@email.cz